Mittie Doyle's most recent trade in Cullinan Oncology Inc was a trade of 79,456 Stock Option (Right to Buy) done . Disclosure was reported to the exchange on Aug. 7, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Cullinan Oncology Inc | Mittie Doyle | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 Aug 2025 | 79,456 | 79,456 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 155,000 | 155,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Mittie Doyle | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jul 2024 | 234,000 | 234,000 | - | - | Stock Option (Right to Buy) |